Lotus Reports June 2026 Revenue of NT$3,399 Million

Taipei, Taiwan, 13 July 2026 — Lotus Pharmaceutical Co., Ltd. (Taiwan Stock Exchange: 1795), a global pharmaceutical leader based in Taiwan, today announced its unaudited consolidated revenue for June 2026 of NT$3,399 million, representing an increase of 225% YoY, mainly driven by the consolidation of Alvogen. Lotus' year-to-date (YTD) June 2026 revenue reached NT$17,453 million, an increase of 84% compared to the same period last year, continued to be supported by Alvogen as well as strong growth in the B2B business.

For the first six months ending June 2026, revenue from US grew 180% YoY to NT$10,732 million for the period, representing c.62% of the total consolidated revenue, driven by the consolidation of Alvogen. Lotus’ Asia business remained stable with revenue of NT$5,255 million, representing c.30% of the Group’s total consolidated revenue. Lotus’ B2B business grew 245% YoY to NT$1,466 million, contributing c.8% of total consolidated revenue, supported by key product launches such as Nintedanib in EU and North America, as well as Enzalutamide in South America, Canada and South Korea.

Founded in 1966, Lotus (1795: TT) is an international pharmaceutical company with a global presence, focused on commercializing both novel and generic pharmaceuticals to provide patients with better, safer, and more accessible medicines. The company boasts a best-in-class R&D and manufacturing platform in Asia, certified by leading regulatory authorities around the world, including the US FDA, EU EMA, Japan PMDA, China FDA, and Brazil ANVISA. Lotus has established partnerships in nearly every major global market, including the U.S., Europe, Japan, China, and Brazil. The company is currently developing and registering over 100 strategically selected pharmaceutical projects across Asia and the U.S., with more than 250 commercial products. Lotus invests in a diversified portfolio, consisting of high-barrier oncology, complex generics, 505(b)2, NCEs, and biosimilars, through both internal R&D investments and licensing-in partnerships to strengthen its portfolio competitiveness